Company Description
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell disease; ELS004, a pharmaceutical grade L-glutamine which has completed phase 1 clinical study to treat diverticulosis; ELS005 in preclinical study for the use and combination of KM10544 to treat blood cancers; ELS003, a lab device/research tool in preclinical study to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis is in preclinical study.
It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor (KM10544) for the treatment of cancers.
The company was founded in 2000 and is headquartered in Torrance, California.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Willis C. Lee M.S. |
Contact Details
Address: 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 United States | |
| Phone | 310-214-0065 |
| Website | emmausmedical.com |
Stock Details
| Ticker Symbol | EMMA |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000822370 |
| CUSIP Number | 29137T101 |
| ISIN Number | US29137T1016 |
| Employer ID | 87-0419387 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Willis C. Lee M.S. | Co-President, Chief Operating Officer and Chairman of the Board |
| Yasushi Nagasaki CPA, CPA | Chief Financial Officer |
| George Sekulich | Co-President, Chief Commercial Officer and Director |
| Dale E. Short J.D. | Legal Consultant and Corporate Secretary |
| Dr. Charles W. Stark Pharm.D, Pharm.D. | Senior Vice President of Medical Affairs, Clinical, Regulatory |
| Kurt H. Kruger M.B.A., M.S. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | 8-K | Current Report |
| Jul 3, 2024 | 8-K | Current Report |
| Jul 3, 2024 | 10-K | Annual Report |
| May 28, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 26, 2024 | 8-K | Current Report |
| Dec 22, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 20, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |